Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…
Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
CHICAGO (Reuters)—Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on May 28. The preliminary results suggest doctors may want to refrain from…
U.S. Insurers Often Limit Biosimilar Coverage
(Reuters Health)—U.S. commercial health plans only covered biosimilar treatments as preferred products in 14% of coverage decisions last year, according to an analysis of publicly available data on coverage decisions.1 Researchers examined records from the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database, which has information on coverage decisions made by 17 of…
Long-Term Biologic Use May Not Raise Melanoma Risk
NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis. However, because the study found trends toward increased melanoma rates with long-term therapy, “a clinically meaningful increase in risk cannot…
Are ANAs More Prevalent in the U.S. Now Than in the Past?
According to a new study, the prevalence of anti-nuclear antibodies (ANAs), the most common biomarker of autoimmunity in the U.S., has increased considerably in recent years among adolescents aged 12–19 years, in both sexes (especially in men), older adults (age ≥50 years) and non-Hispanic whites…
WHO Expects HCQ Safety Findings by Mid-June
ZURICH (Reuters)—The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine (HCQ), probably by mid-June, after safety concerns prompted the group to suspend the malaria drug’s use in a trial on COVID-19 patients. U.S. President Donald Trump and others have pushed HCQ as a possible coronavirus treatment, but the WHO…
As Chinese Authorities Expand Use of Health Tracking Apps, Privacy Concerns Grow
SHANGHAI (Reuters)—China’s health tracking QR codes, which have played a key part in the country’s successful containment of COVID-19, now look set to play a much broader role in daily life as local authorities dream up new uses for the technology. Embedded in the popular WeChat and Alipay smartphone apps, the codes use self-reported and…
Few Medicare Advantage Plans Cover Social Needs for Chronically Ill Patients
(Reuters Health)—Most Medicare Advantage plans are not offering chronically ill enrollees supplemental benefits to address social needs, which were added to the government health program in 2018 in an effort to improve health outcomes and achieve cost savings, a U.S. study suggests.1 Researchers examined publicly available data on benefits and plan design for Medicare Advantage…
Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
(Reuters)—Malaria drug hydroxychloroquine (HCQ), which U.S. President Donald Trump says he has been taking, is tied to increased risk of death in COVID-19 patients, according to a study published in The Lancet.1 The registry analysis, which included data from 671 hospitals in six continents and over 96,000 patients hospitalized with COVID-19, showed that people treated…
U.K. Healthcare Workers Begin COVID-19 HCQ Trial
LONDON (Reuters)—On May 21, British healthcare workers began taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one U.S. President Donald Trump says he has been taking. The COPCOV study will involve more than 40,000 frontline healthcare workers from Europe, Africa, Asia and…
- « Previous Page
- 1
- …
- 189
- 190
- 191
- 192
- 193
- …
- 806
- Next Page »